152 related articles for article (PubMed ID: 11433407)
21. Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer.
Zhou Y; Gou LT; Guo ZH; Liu HR; Wang JM; Zhou SX; Yang JL; Li XA
Mol Med Rep; 2015 Jul; 12(1):147-54. PubMed ID: 25760691
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
23. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
24. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
[TBL] [Abstract][Full Text] [Related]
25. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
[TBL] [Abstract][Full Text] [Related]
26. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
27. Redirected T Cell Cytotoxicity in Cancer Therapy.
Clynes RA; Desjarlais JR
Annu Rev Med; 2019 Jan; 70():437-450. PubMed ID: 30379598
[TBL] [Abstract][Full Text] [Related]
28. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
29. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
30. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
31. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
Satta A; Grazia G; Caroli F; Frigerio B; Di Nicola M; Raspagliesi F; Mezzanzanica D; Zaffaroni N; Gianni AM; Anichini A; Figini M
Front Immunol; 2019; 10():2514. PubMed ID: 31708930
[TBL] [Abstract][Full Text] [Related]
32. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
33. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
34. Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo.
Ren H; Li J; Liu JJ; Guo HL; Jiang T
Asian Pac J Cancer Prev; 2012; 13(6):2795-8. PubMed ID: 22938461
[TBL] [Abstract][Full Text] [Related]
35. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
[TBL] [Abstract][Full Text] [Related]
37. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
38. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
39. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
[TBL] [Abstract][Full Text] [Related]
40. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]